Balyasny Asset Management
VIRX

Balyasny Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Balyasny Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-47,691
Closed -$1.21M – 1685
2019
Q2 		$1.21M Sell
47,691
-15,166
-24% -$587K 0.01% 1024
2019
Q1 		$2.67M Hold
62,857
– – 0.02% 742
2018
Q4 		$915K Hold
62,857
– – 0.01% 927
2018
Q3 		$4.4M Hold
62,857
– – 0.02% 742
2018
Q2 		$4.66M Hold
62,857
– – 0.02% 684
2018
Q1 		$5.98M Hold
62,857
– – 0.03% 662
2017
Q4 		$8.12M Buy
62,857
+5,714
+10% +$536K 0.03% 706
2017
Q3 		$3.88M Hold
57,143
– – 0.02% 797
2017
Q2 		$5.4M Buy
+57,143
New +$6.56M 0.02% 732
2015
Q3 		– Sell
-6,575
Closed -$4.16M – 1435
2015
Q2 		$4.16M Sell
6,575
-514
-7% -$273K 0.03% 633
2015
Q1 		$3.65M Sell
7,089
-4,087
-37% -$2.06M 0.03% 532
2014
Q4 		$5.99M Buy
11,176
+10,557
+1,705% +$4.76M 0.06% 395
2014
Q3 		$927K Buy
+619
New +$896K 0.01% 660

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Balyasny Asset Management's VIRX Position: Q3 2019 in Review

Balyasny Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2019, closing a stake of 47,691 shares — an estimated $1.21M sold.

Balyasny Asset Management first reported a position in VIRX in Q3 2014 and held it in 13 quarters. The position peaked at $8.12M in Q4 2017. 49 funds tracked by Wall St. Rank hold VIRX as of Q3 2019.

  • Balyasny Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Balyasny Asset Management sold 47,691 Viracta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $1.21M.
  • Balyasny Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2014 and held it in 13 quarters.
  • Balyasny Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $8.12M in Q4 2017.
  • 49 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Balyasny Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.